BIOR: מזומנים בחישוב למניה אחת Biora Therapeutics, Inc

Biora Therapeutics, Inc - לוגו גרפי של המנפיק BIOR

Cash per share dynamics correlate with the success of the NaviCap targeted biologic delivery system, while the current status is 0.71. Strict control over the transport of complex components and responsible biological waste disposal support price stability. Such fundamental aspects determine the financial resilience of Biora Therapeutics (BIOR) within the gastrointestinal disease therapy sector.

Biora Therapeutics (BIOR) - מזומנים למניה מ-28.04.2023 עד 14.12.2024

פילוחי מדדים מקיפים ואנליטיקה עבור bioratherapeutics.com (BIOR)

- שער מניה ותחזית מחירי מומחים:
- מדדי זמינות כספים ותזרימי מזומנים:
ניתוח מקיף של החברה:Progenity (BIOR)
סחורת הדגל של Biora Therapeutics

Fundamental liquidity analysis minimizes the risk of capital loss when investing in biopharmaceuticals. This is critical for Biora Therapeutics (BIOR), as geopolitical instability and supply chain disruptions necessitate significant financial reserves. The ratio of total cash to the number of shares, illustrated on the cash position per share chart, measures the real value of "liquid" cash. This indicator demonstrates the company's ability to fund therapy development without emergency borrowing. A stable liquidity level confirms the business's resilience to external shocks.